The 2018 study found that a 90 milligram dose of TurboCBD — made using DehydraTECH — resulted in significantly higher levels of CBD levels in the subjects’ plasma after 90 and 120 minutes than a generic CBD dose.
Only TurboCBD performed better than a placebo after 30 minutes and continued to do so after four hours.
Additionally, mean arterial blood pressure was significantly decreased only with the TurboCBD compared to baseline measures. Cerebral perfusion, a measure of blood to the brain, was shown to increase relative to baselines only with TurboCBD.
Increasing blood to the brain is particularly notable, the company said, since last month it was granted two patents that cover DehydraTech for the treatment of conditions including “neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia.”
The study was conducted in a dozen young male athletes, and researchers concluded that more studies are warranted.
“Further acute and chronic dosing investigations in older and cerebrovascular-compromised patients may shed light on the vascular and clinical impacts of increased CBD bioavailability,” investigators said in the article.
The journal article also referenced a separate study involving a competitor, Lexaria said, which evaluated a similar CBD dose with bioabsorption. The 90mg TurboCBD dose achieved a higher maximum plasma concentration and outperformed the competitor’s 100mg dose up until about 3.5 hours after administration.
The Advanced Therapy article, published September 12, is titled, “Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study.”
Lexaria's share price increased 5.6% to C$0.94 on the CSE on Tuesday and 4.1% to US$0.71 on OTC Markets.
—Updated to include stock movement—
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel